Philip F Halloran1,2,3, Jeff Reeve4, Katelynn S Madill-Thomsen4,3, Zachary Demko5, Adam Prewett5, Paul Billings5. 1. Alberta Transplant Applied Genomics Center, Edmonton, Canada phallora@ualberta.ca. 2. Department of Medicine, University of Alberta, Edmonton, Canada. 3. Transcriptome Sciences Inc., Edmonton, Canada. 4. Alberta Transplant Applied Genomics Center, Edmonton, Canada. 5. Natera, San Carlos, California.
Abstract
BACKGROUND: The relationship between the donor-derived cell-free DNA fraction (dd-cfDNA[%]) in plasma in kidney transplant recipients at time of indication biopsy and gene expression in the biopsied allograft has not been defined. METHODS: In the prospective, multicenter Trifecta study, we collected tissue from 300 biopsies from 289 kidney transplant recipients to compare genome-wide gene expression in biopsies with dd-cfDNA(%) in corresponding plasma samples drawn just before biopsy. Rejection was assessed with the microarray-based Molecular Microscope Diagnostic System using automatically assigned rejection archetypes and molecular report sign-outs, and histology assessments that followed Banff guidelines. RESULTS: The median time of biopsy post-transplantation was 455 days (5 days to 32 years), with a case mix similar to that of previous studies: 180 (60%) no rejection, 89 (30%) antibody-mediated rejection (ABMR), and 31 (10%) T cell-mediated rejection (TCMR) and mixed. In genome-wide mRNA measurements, all 20 top probe sets correlating with dd-cfDNA(%) were previously annotated for association with ABMR and all types of rejection, either natural killer (NK) cell-expressed (e.g., GNLY, CCL4, TRDC, and S1PR5) or IFN-γ-inducible (e.g., PLA1A, IDO1, CXCL11, and WARS). Among gene set and classifier scores, dd-cfDNA(%) correlated very strongly with ABMR and all types of rejection, reasonably strongly with active TCMR, and weakly with inactive TCMR, kidney injury, and atrophy fibrosis. Active ABMR, mixed, and active TCMR had the highest dd-cfDNA(%), whereas dd-cfDNA(%) was lower in late-stage ABMR and less-active TCMR. By multivariate random forests and logistic regression, molecular rejection variables predicted dd-cfDNA(%) better than histologic variables. CONCLUSIONS: The dd-cfDNA(%) at time of indication biopsy strongly correlates with active molecular rejection and has the potential to reduce unnecessary biopsies. CLINICAL TRIAL REGISTRATION NUMBER: NCT04239703.
BACKGROUND: The relationship between the donor-derived cell-free DNA fraction (dd-cfDNA[%]) in plasma in kidney transplant recipients at time of indication biopsy and gene expression in the biopsied allograft has not been defined. METHODS: In the prospective, multicenter Trifecta study, we collected tissue from 300 biopsies from 289 kidney transplant recipients to compare genome-wide gene expression in biopsies with dd-cfDNA(%) in corresponding plasma samples drawn just before biopsy. Rejection was assessed with the microarray-based Molecular Microscope Diagnostic System using automatically assigned rejection archetypes and molecular report sign-outs, and histology assessments that followed Banff guidelines. RESULTS: The median time of biopsy post-transplantation was 455 days (5 days to 32 years), with a case mix similar to that of previous studies: 180 (60%) no rejection, 89 (30%) antibody-mediated rejection (ABMR), and 31 (10%) T cell-mediated rejection (TCMR) and mixed. In genome-wide mRNA measurements, all 20 top probe sets correlating with dd-cfDNA(%) were previously annotated for association with ABMR and all types of rejection, either natural killer (NK) cell-expressed (e.g., GNLY, CCL4, TRDC, and S1PR5) or IFN-γ-inducible (e.g., PLA1A, IDO1, CXCL11, and WARS). Among gene set and classifier scores, dd-cfDNA(%) correlated very strongly with ABMR and all types of rejection, reasonably strongly with active TCMR, and weakly with inactive TCMR, kidney injury, and atrophy fibrosis. Active ABMR, mixed, and active TCMR had the highest dd-cfDNA(%), whereas dd-cfDNA(%) was lower in late-stage ABMR and less-active TCMR. By multivariate random forests and logistic regression, molecular rejection variables predicted dd-cfDNA(%) better than histologic variables. CONCLUSIONS: The dd-cfDNA(%) at time of indication biopsy strongly correlates with active molecular rejection and has the potential to reduce unnecessary biopsies. CLINICAL TRIAL REGISTRATION NUMBER: NCT04239703.
Authors: P F Halloran; J Reeve; E Akalin; O Aubert; G A Bohmig; D Brennan; J Bromberg; G Einecke; F Eskandary; C Gosset; J-P Duong Van Huyen; G Gupta; C Lefaucheur; A Malone; R B Mannon; D Seron; J Sellares; M Weir; A Loupy Journal: Am J Transplant Date: 2017-05-30 Impact factor: 8.086
Authors: Roy D Bloom; Jonathan S Bromberg; Emilio D Poggio; Suphamai Bunnapradist; Anthony J Langone; Puneet Sood; Arthur J Matas; Shikha Mehta; Roslyn B Mannon; Asif Sharfuddin; Bernard Fischbach; Mohanram Narayanan; Stanley C Jordan; David Cohen; Matthew R Weir; David Hiller; Preethi Prasad; Robert N Woodward; Marica Grskovic; John J Sninsky; James P Yee; Daniel C Brennan Journal: J Am Soc Nephrol Date: 2017-03-09 Impact factor: 10.121
Authors: Konrad S Famulski; Declan G de Freitas; Chatchai Kreepala; Jessica Chang; Joana Sellares; Banu Sis; Gunilla Einecke; Michael Mengel; Jeff Reeve; Philip F Halloran Journal: J Am Soc Nephrol Date: 2012-02-16 Impact factor: 10.121
Authors: Jeff Reeve; Georg A Böhmig; Farsad Eskandary; Gunilla Einecke; Gaurav Gupta; Katelynn Madill-Thomsen; Martina Mackova; Philip F Halloran Journal: Am J Transplant Date: 2019-04-10 Impact factor: 8.086
Authors: Katelynn S Madill-Thomsen; Georg A Böhmig; Jonathan Bromberg; Gunilla Einecke; Farsad Eskandary; Gaurav Gupta; Luis G Hidalgo; Marek Myslak; Ondrej Viklicky; Agnieszka Perkowska-Ptasinska; Philip F Halloran Journal: J Am Soc Nephrol Date: 2021-07-12 Impact factor: 10.121
Authors: Yousuf Kyeso; Anshul Bhalla; Alyssa P Smith; Yaqi Jia; Safa Alakhdhair; Stephanie C Ogir; Mohammad Abuzeineh; Daniel C Brennan; Sami Alasfar Journal: Transplant Direct Date: 2021-05-25
Authors: Bogdan Obrișcă; Maria Butiu; Lena Sibulesky; Ramasamy Bakthavatsalam; Kelly D Smith; Idoia Gimferrer; Paul Warner; Gener Ismail; Nicolae Leca Journal: Sci Rep Date: 2022-09-05 Impact factor: 4.996